FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2220346905> ?p ?o ?g. }

• W2220346905 endingPage "394" @default.
• W2220346905 startingPage "385" @default.
• W2220346905 abstract "Objective:This study aimed to compare time on treatment (TOT) among patients treated with everolimus and chemotherapy, two commonly used treatments for hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC).Methods:Postmenopausal women with HR+/HER2- mBC who initiated ≥1 new line of therapy for mBC during 20 July 2012–31 March 2014 after a non-steroidal aromatase inhibitor were identified from MarketScan and PharMetrics databases (2002Q1–2014Q2) using a claims-based algorithm. Patients were classified into treatment groups by regimen and line of therapy, and were followed until discontinuation of therapy, end of insurance eligibility, or data cut-off (30 June 2014). Discontinuation was defined as a treatment gap of ≥60 days; patients who did not discontinue were censored at the end of follow-up. TOT was compared between everolimus, chemotherapy, and capecitabine monotherapy using Kaplan–Meier analyses and multivariable Cox models adjusting for line of therapy, age, insurance, de novo mBC diagnosis, prior use of chemotherapy for mBC, sites of metastases, and Charlson comorbidity index.Results:Across the first four lines of therapies for mBC, a total of 940 everolimus, 3410 chemotherapy, and 721 capecitabine monotherapy regimens were included. Based on the different lines of therapies, the median TOT ranged from 5.5 to 7.2 months for everolimus, 4.3 to 4.7 months for chemotherapy, and 3.5 to 6.0 months for capecitabine monotherapy. Pooling all lines of therapies, everolimus was associated with significantly longer TOT compared to chemotherapy (multivariable-adjusted hazard ratio [HR] = 0.69, 95% confidence interval [CI]: 0.62–0.76) or capecitabine monotherapy (multivariable-adjusted HR = 0.73, 95% CI: 0.64–0.83). Longer TOT was consistently observed for everolimus for each line of therapy.Limitations:Proxies used for identifying HR + /HER2- mBC and treatment line, lack of certain clinical factors in claims data, generalizability limited to commercially insured patients in the US.Conclusions:This study found that HR+/HER2- mBC patients receiving everolimus experienced significantly longer TOT than those receiving chemotherapy overall or capecitabine monotherapy." @default.
• W2220346905 created "2016-06-24" @default.
• W2220346905 creator A5001857305 @default.
• W2220346905 creator A5010721455 @default.
• W2220346905 creator A5010897911 @default.
• W2220346905 creator A5014261732 @default.
• W2220346905 creator A5015566996 @default.
• W2220346905 creator A5036494803 @default.
• W2220346905 creator A5041026389 @default.
• W2220346905 creator A5089194015 @default.
• W2220346905 date "2016-01-16" @default.
• W2220346905 modified "2023-09-26" @default.
• W2220346905 title "Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US" @default.
• W2220346905 cites W1553981116 @default.
• W2220346905 cites W1966561347 @default.
• W2220346905 cites W1967612488 @default.
• W2220346905 cites W1975822581 @default.
• W2220346905 cites W1991219585 @default.
• W2220346905 cites W1994685129 @default.
• W2220346905 cites W1997057722 @default.
• W2220346905 cites W2003355055 @default.
• W2220346905 cites W2031131661 @default.
• W2220346905 cites W2071225937 @default.
• W2220346905 cites W2083675583 @default.
• W2220346905 cites W2090048376 @default.
• W2220346905 cites W2116144791 @default.
• W2220346905 cites W2130207808 @default.
• W2220346905 cites W2131106781 @default.
• W2220346905 cites W2138194420 @default.
• W2220346905 cites W2148858542 @default.
• W2220346905 cites W2157333957 @default.
• W2220346905 cites W2157537974 @default.
• W2220346905 cites W2167188058 @default.
• W2220346905 cites W3004533979 @default.
• W2220346905 cites W4234749243 @default.
• W2220346905 cites W633748798 @default.
• W2220346905 cites W2024293188 @default.
• W2220346905 doi "https://doi.org/10.1185/03007995.2015.1130691" @default.
• W2220346905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26651842" @default.
• W2220346905 hasPublicationYear "2016" @default.
• W2220346905 type Work @default.
• W2220346905 sameAs 2220346905 @default.
• W2220346905 citedByCount "6" @default.
• W2220346905 countsByYear W22203469052017 @default.
• W2220346905 countsByYear W22203469052018 @default.
• W2220346905 countsByYear W22203469052019 @default.
• W2220346905 countsByYear W22203469052021 @default.
• W2220346905 crossrefType "journal-article" @default.
• W2220346905 hasAuthorship W2220346905A5001857305 @default.
• W2220346905 hasAuthorship W2220346905A5010721455 @default.
• W2220346905 hasAuthorship W2220346905A5010897911 @default.
• W2220346905 hasAuthorship W2220346905A5014261732 @default.
• W2220346905 hasAuthorship W2220346905A5015566996 @default.
• W2220346905 hasAuthorship W2220346905A5036494803 @default.
• W2220346905 hasAuthorship W2220346905A5041026389 @default.
• W2220346905 hasAuthorship W2220346905A5089194015 @default.
• W2220346905 hasConcept C121608353 @default.
• W2220346905 hasConcept C126322002 @default.
• W2220346905 hasConcept C143998085 @default.
• W2220346905 hasConcept C207103383 @default.
• W2220346905 hasConcept C2775930923 @default.
• W2220346905 hasConcept C2776694085 @default.
• W2220346905 hasConcept C2777176818 @default.
• W2220346905 hasConcept C2777909004 @default.
• W2220346905 hasConcept C2778336483 @default.
• W2220346905 hasConcept C2778504769 @default.
• W2220346905 hasConcept C2778715236 @default.
• W2220346905 hasConcept C2779699572 @default.
• W2220346905 hasConcept C2781413609 @default.
• W2220346905 hasConcept C44249647 @default.
• W2220346905 hasConcept C526805850 @default.
• W2220346905 hasConcept C530470458 @default.
• W2220346905 hasConcept C71924100 @default.
• W2220346905 hasConceptScore W2220346905C121608353 @default.
• W2220346905 hasConceptScore W2220346905C126322002 @default.
• W2220346905 hasConceptScore W2220346905C143998085 @default.
• W2220346905 hasConceptScore W2220346905C207103383 @default.
• W2220346905 hasConceptScore W2220346905C2775930923 @default.
• W2220346905 hasConceptScore W2220346905C2776694085 @default.
• W2220346905 hasConceptScore W2220346905C2777176818 @default.
• W2220346905 hasConceptScore W2220346905C2777909004 @default.
• W2220346905 hasConceptScore W2220346905C2778336483 @default.
• W2220346905 hasConceptScore W2220346905C2778504769 @default.
• W2220346905 hasConceptScore W2220346905C2778715236 @default.
• W2220346905 hasConceptScore W2220346905C2779699572 @default.
• W2220346905 hasConceptScore W2220346905C2781413609 @default.
• W2220346905 hasConceptScore W2220346905C44249647 @default.
• W2220346905 hasConceptScore W2220346905C526805850 @default.
• W2220346905 hasConceptScore W2220346905C530470458 @default.
• W2220346905 hasConceptScore W2220346905C71924100 @default.
• W2220346905 hasIssue "2" @default.
• W2220346905 hasLocation W22203469051 @default.
• W2220346905 hasLocation W22203469052 @default.
• W2220346905 hasOpenAccess W2220346905 @default.
• W2220346905 hasPrimaryLocation W22203469051 @default.
• W2220346905 hasRelatedWork W1553981116 @default.
• W2220346905 hasRelatedWork W2068460136 @default.
• W2220346905 hasRelatedWork W2139955290 @default.

• next